BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 26873565)

  • 1. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
    Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
    Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis.
    Kim SJ; Choi JY; Hyun SH; Ki CS; Oh D; Ahn YC; Ko YH; Choi S; Jung SH; Khong PL; Tang T; Yan X; Lim ST; Kwong YL; Kim WS;
    Lancet Haematol; 2015 Feb; 2(2):e66-74. PubMed ID: 26687611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
    Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
    J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Prognostic Index for Extranodal Natural Killer/T-Cell Lymphoma:Incorporation of Serum β-2 Microglobulin to PINK.
    Kang S; Cho H; Kim S; Lee K; Kang EH; Park JS; Lee YS; Park CS; Go H; Huh J; Ryu JS; Lee SW; Kim SJ; Kim WS; Yoon SE; Ko YH; Suh C
    Cancer Res Treat; 2023 Jan; 55(1):314-324. PubMed ID: 35381163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk-Dependent Conditional Survival and Failure Hazard After Radiotherapy for Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.
    Liu X; Wu T; Zhu SY; Shi M; Su H; Wang Y; He X; Xu LM; Yuan ZY; Zhang LL; Wu G; Qu BL; Qian LT; Hou XR; Zhang FQ; Zhang YJ; Zhu Y; Cao JZ; Lan SM; Wu JX; Qi SN; Yang Y; Li YX
    JAMA Netw Open; 2019 Mar; 2(3):e190194. PubMed ID: 30821826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extranodal NK/T-cell lymphoma, nasal type: Clinical features, outcome, and prognostic factors in 101 cases.
    Su YJ; Wang PN; Chang H; Shih LY; Lin TL; Kuo MC; Chuang WY; Wu JH; Tang TC; Hung YS; Dunn P; Kao HW
    Eur J Haematol; 2018 Sep; 101(3):379-388. PubMed ID: 29908084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis.
    Wang L; Wang Z; Xia ZJ; Lu Y; Huang HQ; Zhang YJ
    Tumour Biol; 2015 Sep; 36(10):7717-23. PubMed ID: 25935537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis.
    Pak K; Kim BS; Kim K; Kim IJ; Jun S; Jeong YJ; Shim HK; Kim SD; Cho KS
    Am J Otolaryngol; 2018; 39(1):1-5. PubMed ID: 29056243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic value of controlling nutritional status (CONUT) score-based nomogram on extranodal natural killer/T cell lymphoma patients.
    Zhang S; Sun C; Chen X; Li D; Hu L; Zhang M; Zhang X; Zhang H; Ye J; Wang L; Jia T; Zhu T; Miao Y; Wang C; Wang L; Yan D; Shen Z; Sang W
    Ann Hematol; 2023 Jun; 102(6):1433-1442. PubMed ID: 37074377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A proposal for a prognostic index for non-nasal type natural killer/T cell lymphoma after asparaginase-based treatment.
    Chen Z; Fang X; Huang H; Wang Z; Hong H; Chen M; Ren Q; Yao Y; Zhang L; Tian Y; Lin S; Lin T
    Ann Hematol; 2020 Dec; 99(12):2811-2819. PubMed ID: 32975588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma.
    Yhim HY; Kim JS; Mun YC; Moon JH; Chae YS; Park Y; Jo JC; Kim SJ; Yoon DH; Cheong JW; Kwak JY; Lee JJ; Kim WS; Suh C; Yang DH;
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1597-604. PubMed ID: 25963920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Killer/T Cell Lymphoma, Nasal Type: A Retrospective Clinical Analysis in North-Western China.
    Liang R; Wang Z; Bai QX; Gao GX; Yang L; Zhang T; Gu HT; Dong BX; Shu MM; Hao CX; Zhang N; Chen XQ
    Oncol Res Treat; 2016; 39(1-2):45-52. PubMed ID: 26891121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of extranodal NK/T cell lymphoma nasal type.
    Tse E; Kwong YL
    Expert Rev Hematol; 2016 Sep; 9(9):861-71. PubMed ID: 27347812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A modified international prognostic index including pretreatment hemoglobin level for early stage extranodal natural killer/T cell lymphoma.
    Wang L; Xia ZJ; Lu Y; Wang QX; Niu SQ; Huang HQ; Zhang YJ
    Leuk Lymphoma; 2015; 56(11):3038-44. PubMed ID: 25747971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy.
    Yamaguchi M; Suzuki R; Kim SJ; Ko YH; Oguchi M; Asano N; Miyazaki K; Terui Y; Kubota N; Maeda T; Kobayashi Y; Amaki J; Soejima T; Saito B; Shimoda E; Fukuhara N; Tsukamoto N; Shimada K; Choi I; Utsumi T; Ejima Y; Kim WS; Katayama N
    Cancer Sci; 2018 Jun; 109(6):2056-2062. PubMed ID: 29601137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Nomogram for Overall Survival in Extranodal Natural Killer/T-Cell Lymphoma Patients.
    Li K; Wang R; Huang S; Pan X; Chen H; Zhou L; Wei J; Wu C; Zhu X; Liang S; Qu S
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e537-e543. PubMed ID: 30243570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma.
    Kwong YL; Kim SJ; Tse E; Oh SY; Kwak JY; Eom HS; Do YR; Mun YC; Lee SR; Shin HJ; Suh C; Chuang SS; Lee YS; Lim ST; Izutsu K; Suzuki R; Relander T; d'Amore F; Schmitz N; Jaccard A; Kim WS
    Ann Oncol; 2018 Jan; 29(1):256-263. PubMed ID: 29077846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy.
    Zhang YP; Zhang R; Zhu HY; Wang L; Wu YJ; Liang JH; Shi WY; Liu H; Xu W; Li JY
    Cancer Res Treat; 2019 Jan; 51(1):368-377. PubMed ID: 29764116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.